You are viewing: South Korea Immunotherapy Drugs Market analysis
Part of: Immunotherapy Drugs Market (Global)

The South Korea Immunotherapy Drugs Market was valued at $3300 Million in 2024 and projected to reach to $6900 Million by 2029, representing a compound annual growth rate of 15.5%. South Korea's immunotherapy drugs market is poised for sustained expansion through 2029, driven by escalating cancer diagnoses, improved healthcare accessibility, and strong government support for pharmaceutical innovation.

South Korea Immunotherapy Drugs Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Immunotherapy Drugs Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 15.5%, reflecting South Korea's strong healthcare infrastructure and increasing adoption of advanced cancer therapies.
  • South Korea's market growth is driven by rising cancer incidence, government healthcare investments, and the country's position as a leading biotech hub in Asia Pacific. The immunotherapy sector in South Korea is characterized by growing patient awareness and expanding reimbursement coverage for checkpoint inhibitors and CAR-T cell therapies.
  • South Korea's pharmaceutical regulatory environment supports rapid drug approvals, enabling faster market entry for innovative immunotherapy treatments.
  • Between 2024 and 2029, South Korea is expected to see increased clinical trial activity and partnerships between domestic and international biopharmaceutical companies, further accelerating market penetration and therapeutic options available to patients..

Key Market Statistics

  • CAGR (2024-2029) 15.5% CAGR
  • Market Size, 2024 ~USD 3300 Million
  • Forecast, 2029 ~USD 6900 Million
  • Country South Korea

South Korea Immunotherapy Drugs Market Overview

Market Valuation Growth :

South Korea's immunotherapy drugs market is valued at USD 3,300 million in 2024, with projections to reach USD 6,900 million by 2029, representing a 15.5% CAGR and doubling market size within five years.

Advanced Healthcare Infrastructure :

South Korea's robust healthcare system and high adoption rates of cutting-edge cancer therapies position it as a leading market for immunotherapy drugs in the Asia-Pacific region.

Rising Cancer Incidence :

Increasing cancer prevalence in South Korea drives demand for innovative immunotherapy treatments, with growing patient populations seeking advanced therapeutic options beyond traditional chemotherapy.

Outpacing Global Growth :

South Korea's immunotherapy market CAGR of 15.5% exceeds the global average of 15.3%, indicating stronger regional momentum and market penetration compared to worldwide trends.

South Korea Immunotherapy Drugs Market Dynamics

  • The market's 15.5% CAGR reflects increasing patient awareness and physician adoption of immunotherapy as a preferred treatment modality.
  • South Korea's advanced medical infrastructure, coupled with high healthcare spending and favorable reimbursement policies, creates an attractive environment for immunotherapy drug manufacturers.
  • Continued investment in oncology research and development, combined with growing clinical trial activities, will further accelerate market growth and establish South Korea as a key hub for immunotherapy innovation in Asia..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • South Korea's immunotherapy drugs market will double from USD 3,300M (2024) to USD 6,900M (2029), growing at 15.5% CAGR.
    • South Korea's advanced healthcare system and biotech infrastructure position it as a key Asia Pacific immunotherapy hub.
    • Rising cancer prevalence and expanding reimbursement policies in South Korea are primary drivers of market growth.
    • South Korea's streamlined regulatory pathways accelerate immunotherapy drug approvals and market entry compared to global averages.

    Immunotherapy Drugs Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment OTHER IMMUNOTHERAPY DRUGS (Type)
    Forecast Period 2024-2029
    Growth Rate CAGR of 15.3% from 2024 to 2029
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 284.92 (2024)
    Revenue Forecast (Billions) ~USD 580.6 (2029)
    Segments Covered Type, Application, Route Of Administration, End User

    South Korea Immunotherapy Drugs Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Antibody Drugs
    • Cancer Vaccines
    • Inhibitor Drugs
    • Interferons & Interleukins
    • Other Immunotherapy Drugs

    By Application

    • Autoimmune & Inflammatory Diseases
    • Cancer
    • Hematology
    • Neurology
    • Osteology
    • Other Applications

    By Route Of Administration

    • Intravenous Route Of Administration
    • Other Route Of Administration
    • Other Routes Of Administration
    • Subcutaneous Route Of Administration

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Other End Users

    Target Audience

    • Pharmaceutical Manufacturers : Pharmaceutical companies need South Korea market data to evaluate market entry opportunities, assess competitive positioning, and develop localized commercialization strategies for immunotherapy products.
    • Healthcare Investors & PE Firms : Investment professionals require detailed South Korea market analysis to identify high-growth opportunities, assess portfolio companies' regional performance, and make informed capital allocation decisions.
    • Medical Device & Biotech Companies : Biotech firms need South Korea-specific insights to understand market dynamics, identify partnership opportunities, and develop companion diagnostics or supportive technologies for immunotherapy.
    • Healthcare Consultants & Advisors : Consulting firms require granular South Korea market data to support client strategy development, market entry planning, and competitive benchmarking in the immunotherapy sector.
    • Government & Policy Makers : Healthcare policymakers and government agencies need market intelligence to inform healthcare policy, reimbursement decisions, and resource allocation for cancer treatment infrastructure in South Korea.

    Reasons to Buy this Report

    • Market Size & Growth Projections : Access precise valuation data for South Korea's immunotherapy market (USD 3,300M in 2024 to USD 6,900M in 2029) to inform investment decisions and market entry strategies specific to this high-growth region.
    • Competitive Landscape Intelligence : Understand South Korea's unique competitive dynamics, including local and international players, market share distribution, and strategic positioning within Asia's immunotherapy sector.
    • Regulatory & Reimbursement Insights : Gain detailed knowledge of South Korea's healthcare policies, drug approval pathways, and reimbursement mechanisms that directly impact market accessibility and commercial viability.
    • Patient Demographics & Demand Drivers : Identify South Korea-specific cancer incidence trends, patient populations, and treatment preferences to tailor product development and marketing strategies for maximum market penetration.
    • Strategic Growth Opportunities : Discover emerging segments, unmet medical needs, and partnership opportunities within South Korea's immunotherapy ecosystem to capitalize on the 15.5% CAGR expansion.

    Frequently asked questions

    What is the current size of South Korea's immunotherapy drugs market?

    South Korea's immunotherapy drugs market was valued at USD 3,300 million in 2024 and is expected to grow to USD 6,900 million by 2029.

    What is the projected growth rate for immunotherapy drugs in South Korea?

    South Korea's immunotherapy drugs market is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2024 to 2029.

    What factors are driving immunotherapy drug adoption in South Korea?

    Key drivers in South Korea include rising cancer incidence, expanding government healthcare reimbursement, strong biotech infrastructure, and increasing patient awareness of immunotherapy options.

    How does South Korea's immunotherapy market compare to other Asia Pacific countries?

    South Korea's 15.5% CAGR and advanced regulatory environment position it as a leading immunotherapy market in Asia Pacific, supported by its sophisticated healthcare system and biotech capabilities.

    Which immunotherapy drug types are most prevalent in South Korea?

    South Korea's market is dominated by checkpoint inhibitors and CAR-T cell therapies, with expanding adoption driven by clinical evidence and reimbursement coverage expansion.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the immunotherapy drugs market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the immunotherapy drugs market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Immunotherapy  Drugs Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the immunotherapy drugs market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the immunotherapy drugs and other dependent submarkets. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Immunotherapy  Drugs Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunotherapy drugs market.

    Market Definition

    Immunotherapy drugs are a broad category of therapeutic agents that help stimulate the body's immune system to combat diseases. These drugs include antibody therapies, cell & gene therapy, inhibitor drugs, and other drugs such as oncolytic viral therapy and cancer vaccines. These drugs are engineered to enhance the immune response or counteract the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. Immunotherapy drugs are used to treat various medical conditions, including cancer, autoimmune diseases, hematology, osteology, neurology, and other therapy areas (such as ophthalmology, dermatology, and cardiovascular disorders).

    Stakeholders

    • Research Institutes
    • Pharmaceutical & Biotechnology Companies
    • Venture Capitalists and Investors
    • Contract Development & Manufacturing Organizations
    • Government Associations
    • Healthcare Associations/Institutes
    • Business Research & Consulting Service Providers

    Report Objectives

    • To define, describe, and forecast the immunotherapy market based on type,  application, route of administrration, end user, and region
    • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall immunotherapy drugs market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), Latin America, Middle East and Africa
    • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
    • To track and analyze competitive developments, such as partnerships, collaborations, agreements, and acquisitions, in the immunotherapy drugs market
    • Micromarkets are the further segments and subsegments of the immunotherapy drugs market.
    • Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

    Available Customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    • Company Information: Detailed analysis and profiling of additional market players (up to five)
    • Geographic Analysis: Further breakdown of the Rest of Europe market, by country, based on approvals and feasibility. Further breakdown of the Rest of Asia Pacific market, by country, based on approvals and feasibility

    Get the Full Immunotherapy Drugs Market Report

    Full forecast, segment splits, and company analysis for all Immunotherapy Drugs Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status